title: INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: SIX YEARS OUTCOME.
abstract: OBJECTIVE
  To report the visual outcome after 6-year follow-up in highly myopic eyes with choroidal neovascularization treated with anti-vascular endothelial growth factor drugs.
  
  
  METHODS
  Retrospective, nonrandomized, multicenter, consecutive, and interventional case series.
  
  
  RESULTS
  Seventy-eight patients were treated with intravitreal bevacizumab and 19 with ranibizumab. Mean age of the patients was 56.5 years (SD, 13.3). The average number of letters read was 56.7 (SD, 19.0) at baseline; 65.7 (SD, 18.4) at 12 months; 63.6 (SD, 20.6) at 24 months; 62.4 (SD, 21.4) at 36 months; 60.6 (SD, 22.0) at 48 months; 58.9 (SD, 22.9) at 60 months, and 58.4 (SD, 22.7) at 72 months (P < 0.01, between initial vs. 12, 24, and 36 months; P = 0.07, 0.3, and 0.5 between initial vs. 48, 60, and 72 months, respectively; Student's t-test paired data). The mean total number of intravitreal injections was 3.3 (SD, 2.3; range, 1-9).
  
  
  CONCLUSIONS
  Bevacizumab and ranibizumab are effective therapies and show similar clinical effects in myopic eyes with choroidal neovascularization. Visual acuity gain is maintained at a 3-year follow-up. The improvement is no longer statistically significant at Years 4, 5, and 6.
authors.affiliation: *Department of Ophthalmology, Castilla La Mancha University, Albacete and Baviera European Institute of Retina, Alicante, Spain; †Pío del Río Hortega University Hospital, Department of Ophthalmology, Valladolid and Oftalvist, Retina Unit, Madrid, Spain; ‡University of the Basque Country (Surgical-Clinical Institute of Ophthalmology) and San Eloy Hospital, Bilbao, Spain; §Bellvitge University Hospital, Department of Ophthalmology, Barcelona, Spain; ¶Navarra University Hospital, Department of Ophthalmology, Pamplona, Spain; **Department of Sense Organs of Faculty of Medicine of University of Porto and Department of Ophthalmology of Hospital of São João, Porto, Portugal; and ††Faculty of Medicine University of Coimbra (FMUC), Coimbra Hospital and University Centre (CHUC) and Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: Javier A
authors.initials: JA
authors.lastname: Montero
authors.forename: Javier
authors.initials: J
authors.lastname: Araiz
authors.forename: Luis
authors.initials: L
authors.lastname: Arias
authors.forename: Alfredo
authors.initials: A
authors.lastname: García-Layana
authors.forename: Angela
authors.initials: A
authors.lastname: Carneiro
authors.forename: Marta S
authors.initials: MS
authors.lastname: Figueroa
authors.forename: Rufino
authors.initials: R
authors.lastname: Silva
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D000069579:Ranibizumab / Q000008:administration & dosage*; D012044:Regression Analysis; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014786:Vision Disorders / Q000188:drug therapy; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab